Literature DB >> 2411180

Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7). A report of the French-American-British Cooperative Group.

J M Bennett, D Catovsky, M T Daniel, G Flandrin, D A Galton, H R Gralnick, C Sultan.   

Abstract

For the diagnosis of M7, the bone marrow aspirate shows a leukemic cell infiltrate that comprises 30% or more of all cells. These cells are identified as being of megakaryocyte lineage by the platelet peroxidase reaction on electron microscopy or by tests with monoclonal or polyclonal platelet-specific antibodies. Myelofibrosis or increased bone marrow reticulin are a prominent aspect in most patients with M7. In patients with increased reticulin, the bone marrow sample may be difficult to obtain and the counts done on the marrow films may be misleading. In these patients, the diagnosis of M7 should be based on excellent bone marrow biopsy sections that show an excess of blasts and, at times, increased numbers of maturing megakaryocytes; and on the presence of unequivocal megakaryoblasts in the peripheral blood or bone marrow (or both) as shown by immunologic techniques.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2411180     DOI: 10.7326/0003-4819-103-3-460

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  67 in total

1.  Comprehensive review of adult acute myelogenous leukemia: cytomorphological, enzyme cytochemical, flow cytometric immunophenotypic, and cytogenetic findings.

Authors:  C H Dunphy
Journal:  J Clin Lab Anal       Date:  1999       Impact factor: 2.352

2.  The role of matched sibling donor allogeneic stem cell transplantation in pediatric high-risk acute myeloid leukemia: results from the AML-BFM 98 study.

Authors:  Jan-Henning Klusmann; Dirk Reinhardt; Martin Zimmermann; Bernhard Kremens; Josef Vormoor; Michael Dworzak; Ursula Creutzig; Thomas Klingebiel
Journal:  Haematologica       Date:  2011-09-20       Impact factor: 9.941

Review 3.  Myelodysplastic syndromes.

Authors:  I M Hann
Journal:  Arch Dis Child       Date:  1992-07       Impact factor: 3.791

4.  Leukaemia complicating treatment for Hodgkin's disease: the experience of the British National Lymphoma Investigation.

Authors:  S Devereux; T G Selassie; G Vaughan Hudson; B Vaughan Hudson; D C Linch
Journal:  BMJ       Date:  1990-11-10

5.  Disomic homozygosity in 21-trisomic cells: a mechanism responsible for transient myeloproliferative syndrome.

Authors:  K Abe; T Kajii; N Niikawa
Journal:  Hum Genet       Date:  1989-07       Impact factor: 4.132

Review 6.  A classification of acute leukaemia for the 1990s.

Authors:  D Catovsky; E Matutes; V Buccheri; V Shetty; J Hanslip; N Yoshida; R Morilla
Journal:  Ann Hematol       Date:  1991-02       Impact factor: 3.673

7.  Constitutional hypomorphic telomerase mutations in patients with acute myeloid leukemia.

Authors:  Rodrigo T Calado; Joshua A Regal; Mark Hills; William T Yewdell; Leandro F Dalmazzo; Marco A Zago; Peter M Lansdorp; Donna Hogge; Stephen J Chanock; Elihu H Estey; Roberto P Falcão; Neal S Young
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-15       Impact factor: 11.205

8.  Acute lymphoblastic leukaemia in adults: immunological subtypes and clinical features at presentation.

Authors:  M B van't Veer; W L van Putten; L F Verdonck; G J Ossenkoppele; B Löwenberg; J C Kluin-Nelemans; P W Wijermans; H C Schouten; W Sizoo; A W Dekker
Journal:  Ann Hematol       Date:  1993-06       Impact factor: 3.673

9.  Reproducibility of the morphological diagnostic criteria for acute myeloid leukemia: the GIMEMA group experience.

Authors:  G L Castoldi; V Liso; S Fenu; M L Vegna; F Mandelli
Journal:  Ann Hematol       Date:  1993-04       Impact factor: 3.673

10.  Prognostic significance of CD7+CD56+ phenotype and chromosome 5 abnormalities for acute myeloid leukemia M0.

Authors:  Ritsuro Suzuki; Makoto Murata; Masahiro Kami; Shigeki Ohtake; Norio Asou; Yoshihisa Kodera; Masao Tomonaga; Yasufumi Masaki; Shuya Kusumoto; Jin Takeuchi; Shin Matsuda; Hisamaru Hirai; m Seiichi Yorimitsu; Nobuyuki Hamajima; Masao Seto; Masanori Shimoyama; Ryuzo Ohno; Yasuo Morishima; Shigeo Nakamura
Journal:  Int J Hematol       Date:  2003-06       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.